/XERS
XERS Stock - Xeris Biopharma Holdings, Inc.
Healthcare|BiotechnologyNASDAQ
$7.34+4.71%
+$0.33 (+4.71%) • Dec 19
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.63
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.82
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+83.9%upside
Target: $13.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for XERS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.27 – $7.41
TARGET (TP)$13.50
STOP LOSS$6.75
RISK/REWARD1:10.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.94
52W High$10.08
52W Low$3.14
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $203.07M | $163.91M | $110.25M | $49.59M | $20.43M |
| Gross Profit | $166.24M | $135.27M | $87.61M | $36.27M | $11.11M |
| Gross Margin | 81.9% | 82.5% | 79.5% | 73.1% | 54.4% |
| Operating Income | $-33,646,000 | $-44,010,000 | $-81,940,000 | $-115,156,000 | $-83,546,000 |
| Net Income | $-54,836,000 | $-62,255,000 | $-94,660,000 | $-122,725,000 | $-91,140,000 |
| Net Margin | -27.0% | -38.0% | -85.9% | -247.5% | -446.0% |
| EPS | $-0.37 | $-0.45 | $-0.70 | $-1.55 | $-2.14 |
Company Overview
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
83%
Hold / Neutral
1
17%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish1 Neutral/Bearish
Price Targets
$6
Average Target
↓ 18.3% Downside
Now
$3
Low
$6
Average
$10
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Overweight | $9 |
| August 12th 2025 | H.C. Wainwright | Resumed | Buy | $10 |
| November 11th 2024 | Piper Sandler | Downgrade | Neutral | $3 |
| March 28th 2024 | Oppenheimer | Initiation | Outperform | $5 |
| August 28th 2023 | Craig Hallum | Initiation | Buy | $4.5 |
| October 21st 2022 | Jefferies | Initiation | Buy | $4 |
| April 28th 2022 | Craig Hallum | Initiation | Buy | $6.5 |
Earnings History & Surprises
XERSBeat Rate
61%
Last 18 quarters
Avg Surprise
+4.4%
EPS vs Estimate
Beats / Misses
11/7
Last 12 quarters
Latest EPS
$0.00
Q4 2025
EPS Surprise History
Q1 24
-11.1%
$-0.10vs$-0.09
Q2 24
-16.7%
$-0.14vs$-0.12
Q3 24
+9.1%
$-0.10vs$-0.11
Q4 24
+33.3%
$-0.06vs$-0.09
Q1 25
+62.5%
$-0.03vs$-0.08
Q2 25
+14.3%
$-0.06vs$-0.07
Q3 25
+66.7%
$-0.01vs$-0.03
Q4 25
-65.0%
$0.00vs$0.01
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $0.03 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.01 | $0.00 | -65.0% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.03 | $-0.01 | +66.7% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q1 2025 | Mar 6, 2025 | $-0.08 | $-0.03 | +62.5% | ✓ BEAT |
Q4 2024 | Nov 8, 2024 | $-0.09 | $-0.06 | +33.3% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.11 | $-0.10 | +9.1% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.12 | $-0.14 | -16.7% | ✗ MISS |
Q1 2024 | Mar 6, 2024 | $-0.09 | $-0.10 | -11.1% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.12 | $-0.09 | +25.0% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.13 | $-0.14 | -7.7% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-0.17 | $-0.12 | +29.4% | ✓ BEAT |
Q1 2023 | Mar 8, 2023 | $-0.16 | $-0.10 | +37.5% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.17 | $-0.14 | +17.6% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.23 | $-0.19 | +17.4% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.24 | $-0.25 | -4.2% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-0.21 | $-0.42 | -100.0% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.37 | $-0.36 | +2.7% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.31 | $-0.41 | -32.3% | ✗ MISS |
Latest News
Barclays Initiates Coverage On Xeris Biopharma Holdings with Overweight Rating, Announces Price Target of $9
📈 PositiveBenzinga•Dec 9, 2025, 04:28 PM•Also:
Xeris Announces Notice Of Allowance From USPTO Covering Its XP-8121 Patent Application
📈 PositiveBenzinga•Dec 1, 2025, 12:15 PM
Xeris Biopharma Holdings shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Nov 6, 2025, 02:27 PM
Xeris Biopharma Holdings Raises FY2025 Sales Guidance from $280.000M-$290.000M to $285.000M-$290.000M vs $286.467M Est
➖ NeutralBenzinga•Nov 6, 2025, 12:03 PM
Xeris Biopharma Holdings Q3 Sales $74.380M Beat $74.180M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:02 PM
American Regent And Xeris Pharmaceuticals Launch Gvoke VialDx, First Concentrated Liquid Glucagon For Diagnostic GI Procedures
📈 PositiveBenzinga•Aug 27, 2025, 12:39 PM
Xeris Announces US Patent Listing In Orange Book Extending Recorlev Protection To 2040 for Endogenous Cushing's Syndrome Treatment
📈 PositiveBenzinga•Aug 25, 2025, 11:12 AM
Frequently Asked Questions about XERS
What is XERS's current stock price?
Xeris Biopharma Holdings, Inc. (XERS) is currently trading at $7.34 per share. The stock has moved +4.71% today.
What is the analyst price target for XERS?
The average analyst price target for XERS is $13.50, based on 1 analyst.
What sector is Xeris Biopharma Holdings, Inc. in?
Xeris Biopharma Holdings, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is XERS's market cap?
Xeris Biopharma Holdings, Inc. has a market capitalization of $1.22 billion, making it a small-cap company.
Does XERS pay dividends?
No, Xeris Biopharma Holdings, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABCL
AbCellera Biologics Inc.
$3.60
Mkt Cap: $1.1B
BCRX
BioCryst Pharmaceuticals, Inc.
$7.41
Mkt Cap: $1.6B
BHVN
Biohaven Ltd.
$10.85
Mkt Cap: $1.1B
CLDX
Celldex Therapeutics, Inc.
$25.60
Mkt Cap: $1.7B
HRMY
Harmony Biosciences Holdings, Inc.
$37.81
Mkt Cap: $2.2B
IMCR
Immunocore Holdings plc
$36.01
Mkt Cap: $1.8B
JANX
Janux Therapeutics, Inc.
$13.79
Mkt Cap: $0.8B
MAZE
Maze Therapeutics, Inc.
$41.71
Mkt Cap: $2.0B
SION
Sionna Therapeutics, Inc.
$42.37
Mkt Cap: $1.9B
VERA
Vera Therapeutics, Inc.
$51.22
Mkt Cap: $3.3B
Explore stocks similar to XERS for comparison